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Nuclear receptors play an important role in transcriptional regulation of
diverse cellular processes and is also relevant in diseases such as cancer.
In breast cancer, the nuclear receptors – estrogen receptor (ER) and
progesterone receptor (PR) are classical markers of the disease and are
used to classify breast cancer subtypes. Using a recently developed
afﬁnity puriﬁcationMS technique (RIME) [1], we investigate the protein
interactors of ER and PR in breast cancer cell lines upon stimulation
by the ligands – estrogen and progesterone. The data is deposited at
proteomeXchange (PXD002104) and is part of a publication [2] that
explains the link between the two nuclear receptors and potential
consequences of this in breast cancer. In this manuscript, we describe
themethodology used and provide details on experimental procedures,
analysis methods and analysis of raw data. The purpose of this article is
to enable reproducibility of the data and provide technical recommen-
dations on performing RIME in hormonal contexts.
& 2015 The Authors. Published by Elsevier Inc. This is an open access
article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Speciﬁcations tableSubject area Biology, ChemistryMore speciﬁc
subject areaChromatin biology and Mass spectrometryType of data MS data and annotationsier Inc. This is an open access article under the CC BY-NC-ND license
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acquiredThermo Orbitrap VelosData format Raw (.raw ﬁles), MGF ﬁles, analysed Excel lists
Experimental factors Breast cancer cell lines were grown in SILAC labeled media, hormone treated, formaldehyde crosslinked
and RIME performed of ER and PR
Experimental
featuresInteractomes of ER and PR with differential hormone treatmentsData source location Cambridge, United Kingdom
Data accessibility Data deposited at proteomeXchange (PXD002104)Value of the data This data exhibits quantitative (SILAC) RIME proteomics experiments and details on the
methodology. Comprehensive analysis of the ER and PR interactome under estrogen alone or Estrogenþ
Progesterone conditions. Co-stimulation of estrogen and progesterone leads to an interaction between the two receptors.1. Experimental design – materials and methods
The data presented here uses Rapid ImmunoprecipitationMass spectrometry of Endogenous protein
(RIME) [1] to interrogate the interactomes of the estrogen Receptor (ER) and progesterone receptor (PR)
under either estrogenic conditions (complete media) or with additional progesterone treatment. This
proteomics study describes the effect of activating a single nuclear receptor or two receptors with their
respective ligands in breast cancer cell lines and is part of a study that identiﬁes the synergistic roles of
ER and PR in breast cancer [2]. All experiments were performed in the breast cancer cell lines MCF-7
and T47-D, both of which express sufﬁcient levels of ER and PR.1.1. Growth conditions and hormone treatments
The ERþ/PRþ cell lines, MCF-7 and T47-D cells were grown in SILAC DMEM (PAA; E15-086)
supplemented with 10% dialysed serum (Sigma-Aldrich; F0392) and 800 mM L-lysine 13C615N2
hydrochloride and 482 mM L-arginine 13C6 15N4 hydrochloride (Sigma-Aldrich) for ‘heavy’-labelled
media or 800 mM L-lysine 12C614N2 hydrochloride and 482 mM L-arginine 12C614N4 hydrochloride for
‘light’-labelled media. Alternative SILAC DMEM compatible with MCF-7 and T47-D cells also yield
similar results (Thermo; 89985). Cells switching to SILAC media were also supplemented with
additional glutamate. To avoid clonal effects, cells are expanded in SILAC media and harvested
immediately after an appropriate level of label incorporation is achieved, thus heavy or light labeled
cells were not maintained long term. Cells were obtained from ATCC. Culture cells were supplemented
with 100 nM of progesterone or 10 nM R5020 for 4 h. The ligands were diluted in DMEM (no serum)
and all dilutions and stock solutions were maintained in glass vials. Control cells were supplemented
with an equivalent amount of vehicle (ethanol).
Cells were grown in 15 cm culture (Nunc) dishes and harvested at 80% conﬂuency. Cells were
crosslinked by replacing media with fresh pre-warmed DMEM (10 ml, without FBS) containing 1%
formaldehyde (TEBU Bioscience; 18814). After 8 min of crosslinking, 1 ml of 2.5 M glycine was added to
each plate (ﬁnal volume 11 ml). Plates of cells were thenwashed twice with cold PBS before the cells were
harvested in 1 ml of PBS using a cell scraper. The cells were pelleted at 2000 G and PBS was removed. Cells
were then frozen at 80 1C for storage and subsequent steps were performed at a later date.
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20 μg of ER (Santa Cruz; sc-543, lot-A2213) or PR (Santa Cruz; sc-7208, lot H2312) antibodies
conjugated to 100 μl of magnetic Protein A beads were used for each RIME experiment. To prepare the
conjugate, 100 μl of beads were washed three times with 1 ml of 0.5% BSA in PBS. The beads were then
resuspended in 100 μl of this buffer and 20 μgs of antibody was added. The mixture was topped up
with additional BSA/PBS buffer (250 μl) and then incubated overnight at 4 1C (rotating). The beads
were then washed again 3 times in BSA/PBS to remove any unconjugated antibody and then
resuspended in 100 μl of BSA/PBS buffer. This ﬁnal antibody-bead conjugate is then subsequently
added to the cell lysate for immunoprecipitation.
1.3. Cell lysis, sonication and immunoprecipitation (RIME)
For each RIME experiment, approximately 20 million cells each (equivalent to 215 cm2 dish) of
treatment and control grown in heavy or light SILAC conditions were mixed. The cells are then
resuspended in 10 ml of LB1 buffer (50 mM HEPES-KOH [pH 7.5], 140 mM NaCl, 1 mM EDTA, 10%
glycerol, 0.5% NP-40 or Igepal CA-630, and 0.25% Triton X-100) and incubated at 4 1C for 10 min
(rotating). The cells were then pelleted at 2000 g for 5 mins (4 1C) and the supernatant removed. The
resulting pellet was then resuspended in 10 ml of LB2 buffer (10 mM Tris–HCL [pH 8.0], 200 mM NaCl,
1 mM EDTA, and 0.5 mM EGTA) and incubated again at 4 1C for 5 min (rotating). This was then
centrifuged at 2000 g for 5 mins and the supernatant was removed. This pellet was then resuspended
in LB3 buffer (10 mM Tris–HCl [pH 8], 100 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 0.1% Na-deoxycholate,
and 0.5% N-lauroylsarcosine). Each plate worth of cell pellets (approx. 10–20 million cells) were
resuspended in 300 μl of LB3 and transferred to a 1.5 ml eppendorf tube and sonicated in a bioruptor
sonicator for 15 min (30 s on/30 s off, high setting). The sonicated lysates for each plate were then
pooled and 10% volume of 10%Triton-X solution was added. This mixture was then centrifuged at
12,000 g for 10 min to pellet cell debris. The supernatant was carefully removed and 100 μl of beads
pre-incubated with antibody was added. This IP mixture was then incubated overnight at 4 1C
(rotating). Subsequently, the lysate-bead mixture was then placed on a magnetic rack and the
supernatant removed. The resulting beads were then washed 10 times in RIPA buffer (50 mM HEPES
pH 7.6, 1 mM EDTA, 0.7% Na deoxycholate, 1% NP-40, 0.5 M LiCL) and then twice in 1 ml of 100 mM
ammonium hydrogen carbonate (freshly prepared). After the last wash, the beads were brieﬂy spun
down and any residual liquid was removed. Beads were then either frozen (20 1C) or directly
processed for peptide digestion.
1.4. Tryptic digestion and MS
Bead bound protein complexes were then digested by adding 100 ng of trypsin in 10 μL of 100 mM
NH4HCO3 onto the beads. The bead mixture was brieﬂy vortexed and then incubated overnight at
37 1C. The next day, an additional 10 μl of trypsin was added, vortexed and incubated for an additional
4 h. The supernatant was then removed and transferred to a glass vial containing 1 μl of formic acid
(5% ﬁnal concentration). The acidiﬁed samples were then bound to a C18 Ultra-Micro Spin Column
(Harvard Apparatus) and washed using a 0.1% solution of Formic Acid. Elution was then carried out
using a 60% solution of acetonitrile.
The samples were then re-suspended in 0.1% formic acid and loaded on-to an LTQ Orbitrap Velos
(Thermo) mass spectrometer and then run using settings previously described [1].
1.5. Data analysis
The acquired MS spectra were then analysed using Proteome Discoverer v1.3 (Thermo Scientiﬁc) in
combination with the Mascot search engine (Matrix Science) against the SwissProt human database.
The search parameters allowed for one missed cleavage and a precursor ion search tolerance of
10 ppmwith 0.6 Da for MS/MS ions. Additionally, the variable modiﬁcations oxidized methionine and
Fig. 1. Example mass spectra (MS1) of peptide ions used for quantiﬁcation in an ER RIME experiment with or without
progesterone treatment where ER and PR association is seen only after progesterone treatment (PRIDE Accession
PDX002104452234/JP517). (A) MS1 spectrum of the 2þ peptide ions corresponding to the peptide sequence SIILLNSG-
VYTFLSSTLK from the human estrogen receptor (AC P03372). Both the light (SIILLNSGVYTFLSSTLK [6C12 2N14], monoisotopic peak
at m/z 978.55695) and heavy (SIILLNSGVYTFLSSTLK [6C13 2N15], monisotopic peak at m/z 982. 56415) versions of the peptide are
indicated. These originate from the estrogenþprogesterone treated cells and the estrogen alone cells respectively. Quantiﬁcation
of the peak areas resulted in a 1:1 (H:L) ratio. (B) MS1 spectrum of the 3þ peptide ions corresponding to the peptide sequence
ALSVEFPEMMSEVIAAQLPK from the human progesterone receptor (AC P06401). Both the light (ALSVEFPEMMSEVIAAQLPK [6C12
2N14], monoisotopic peak at m/z 730.71130) and heavy (ALSVEFPEMMSEVIAAQLPK [6C13 2N15], monoisotopic peak at m/z
732.95355) versions of the peptide are indicated. These originate from the estrogenþprogesterone treated cells and the estrogen
alone cells respectively. Quantiﬁcation of the peak areas resulted in a 1:15 (H:L)ratio.
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heavy amino acid SILAC settings were set as ﬁxed modiﬁcations. A false discovery rate (FDR) was
calculated using a reversed decoy database with a target of less than 1%. For each RIME experiment,
only proteins identiﬁed in both cell lines were considered (Fig. 1).Acknowledgments
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